Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan M Domchek

Showing results (251-260 of 361) with videos related to

Pageof 37
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020Mary B Daly, Robert Pilarski, Matthew B Yurgelun, et al.
Breast Cancer Research : BCR|April 20, 2012
Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriersAna-Teresa Maia, Antonis C Antoniou, Martin O'Reilly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2017
Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based OutreachGoli Samimi, Marcus Q Bernardini, Lawrence C Brody, et al.
NPJ Breast Cancer|May 11, 2026
Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2)Yara Abdou, Mariya Rozenblit, Dario Trapani, et al.
Cancer Discovery|September 30, 2024
Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein BiomarkersJamie E Medina, Akshaya V Annapragada, Pien Lof, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 11, 2024
Development of a Breast Cancer Risk Prediction Model Integrating Monogenic, Polygenic, and Epidemiologic RiskSarah S Kalia, Nicholas J Boddicker, Siddhartha Yadav, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMary B Daly, Tuya Pal, Michael P Berry, et al.
The New England Journal of Medicine|June 3, 2021
Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast CancerAndrew N J Tutt, Judy E Garber, Bella Kaufman, et al.
Breast Cancer Research and Treatment|April 28, 2016
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriersDana Madorsky-Feldman, Miri Sklair-Levy, Tamar Perri, et al.
JAMA Oncology|July 2, 2016
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA MutationsCatherine A Shu, Malcolm C Pike, Anjali R Jotwani, et al.
Pageof 37

Showing results (251-260 of 361) with videos related to

Sort By:
Pageof 37
Journal of the National Comprehensive Cancer Network : JNCCN|April 8, 2020
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020Mary B Daly, Robert Pilarski, Matthew B Yurgelun, et al.
Breast Cancer Research : BCR|April 20, 2012
Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriersAna-Teresa Maia, Antonis C Antoniou, Martin O'Reilly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2017
Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based OutreachGoli Samimi, Marcus Q Bernardini, Lawrence C Brody, et al.
NPJ Breast Cancer|May 11, 2026
Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2)Yara Abdou, Mariya Rozenblit, Dario Trapani, et al.
Cancer Discovery|September 30, 2024
Early Detection of Ovarian Cancer Using Cell-Free DNA Fragmentomes and Protein BiomarkersJamie E Medina, Akshaya V Annapragada, Pien Lof, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|September 11, 2024
Development of a Breast Cancer Risk Prediction Model Integrating Monogenic, Polygenic, and Epidemiologic RiskSarah S Kalia, Nicholas J Boddicker, Siddhartha Yadav, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 6, 2021
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyMary B Daly, Tuya Pal, Michael P Berry, et al.
The New England Journal of Medicine|June 3, 2021
Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast CancerAndrew N J Tutt, Judy E Garber, Bella Kaufman, et al.
Breast Cancer Research and Treatment|April 28, 2016
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriersDana Madorsky-Feldman, Miri Sklair-Levy, Tamar Perri, et al.
JAMA Oncology|July 2, 2016
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA MutationsCatherine A Shu, Malcolm C Pike, Anjali R Jotwani, et al.
Pageof 37